Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 3
Submit an article Journal homepage
95
Views
12
CrossRef citations to date
0
Altmetric
Miscellaneous

Modulation of Th1 and Th2 responses for immunotherapy

Francis J Dumont Department of Immunology, Merck Research Laboratories, RY80W107, 126 Lincoln Avenue, Rahway 07065 NJ, USA, Tel.: +1 732 594 7516;, E-mail: [email protected]
Pages 341-367 | Published online: 25 Feb 2005

Bibliography

  • JANKOVIC D, LIU Z, GAUSE WC: Thl-and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Innnunol (2001) 22:450–457.
  • ••Excellent overview of current knowledgeon Thl and Th2 cell development pathways.
  • SMYTH MJ, GODFREY DI, TRAPANI JA: A fresh look at tumour immunosurveillance and immunotherapy. Nat. Inonunol (2001) 2:293–299.
  • DUMONT FJ: Immunosuppressive strategies for prevention of transplant rejection. Expert Opin. flier. Patents. (2001) 11(3)377–404.
  • MARRACK P, KAPPLER J, KOTZIN BL: Autoimmune disease: why and where it occurs. Nat. Med. (2001) 7:899–905.
  • ROMAGNANI S: The role of lymphocytes in allergic disease. J. Allergy Clin. Inonunol. (2000) 105:399–408.
  • WILLS-KARP M, SANTELIZ J, KARP CL: The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat. Rev. Irionunol. (2001) 1:69–75.
  • MOSMANN TR, COFFMAN RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev Innnunol. (1989) 7:145–173.
  • •First description of Thl/Th2 paradigm.
  • FINKELMAN FD, URBAN JFJ: The other side of the coin: the protective role of the TH2 cytokines. J. Allergy Clin. Inonunol (2001) 107:772–780.
  • LUCEY DR, CLERICI M, SHEARER GM: Type 1 and Type 2 cytokine dysregulation in human infectious, neoplastic and inflammatory diseases. Clin. Microbial. Rey (1996) 9:532–562.
  • ROMAGNANI S: The Thl/Th2 paradigm. Inonunol. Today(1997) 18:263–266.
  • ••Extension of Th1/Th2 paradigm to humanimmunopathology.
  • WANG X, MOSMANN T: In vivo priming of CD4 T-cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-7 and can subsequently differentiate into IL-4- or IFN-y-secreting cells. J. Exp. Med (2001) 194:1069–1080.
  • MURPHY KM, OUYANG W, FARRAR JD et al.: Signaling and transcription in T- development. Ann. Rev. Inonunol. (2000) 18:451–494.
  • •Review of molecular mechanisms of Thl and Th2 cell differentiation.
  • LIU YJ, KANZLER H, SOUMELIS V, GILLIET M: Dendritic cell lineage, plasticity and cross-regulation. Nat. Inonunol (2001) 2:585–589.
  • LEITENBERG D, BOTTOMLY K: Regulation of naive T-cell differentiation by varying the potency of TCR signal transduction. Seinin. Inonunol. (1999) 11:283–292.
  • NOBLE A, THOMAS MJ, KEMENY DM: Early Thl/Th2 cell polarization in the absence of IL-4 and IL-12: T-cell receptor signaling regulates the response to cytokines in CD4 and CD8 T-cells. Ear: I Inonunol. (2001) 31:2227–2235.
  • SCHAEFFER EM, YAP GS, LEWIS CM et al.: Mutation of Tec family kinases alters T-helper cell differentiation. Nat. Inonunol. (2001) 2:1183–1188.
  • SALOMON B, BLUESTONE JA: Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann. Rev Innnunol. (2001) 19:225–252.
  • MCINTIRE JJ, UMETSU SE, AKBARI 0 et al.: Identification of Tapr (an airway hyper-reactivity regulatory locus) and the linked Tim gene family. Nat. Inonunol (2001) 2:1109–1116.
  • ••Identifies a novel genetic locus thatregulates Th2 development.
  • GATELY MK, REZETTI LM, MAGRAM J et al: The interleukin-12/interleuldn-12-receptor system: role in normal and pathologic immune responses. Ann. Rev Inonunol. (1998) 16:495–521.
  • NELMS K, KEEGAN AD, ZAMORANO J et al: The IL-4 receptor: signaling mechanisms and biologic functions. Ann. Rev Inonunol (1999) 17:701–738.
  • GROGAN JL, MOHRS M, HARMON B et al.: Early transcription and silencing of cytokine genes underlie polarization of T-helper subsets. Immunity (2001) 14:205–215.
  • GODFREY DI, HAMMOND KJ, POULTON LD et al.: NKT cells: facts, functions and fallacies. Inonunol. Today (2000) 21:573–583.
  • KARULIN AY, HESSE MD, YIP HC, LEHMANN PV: Indirect IL-4 pathway in Type 1 immunity. J. Inonunol (2002) 168:545–553.
  • NAKANISHI K, YOSHIMOTO T, TSUTSUI H, OKAMURA H: Interleuldn-18 regulates both Thl and Th2 responses. Ann. Rev. Inonunol. (2001) 19:423–474.
  • MULLEN AC, HUTCHINS AS, VILLARINO AV et al.: Cell cycle controlling the silencing and functioning of mammalian activators. Curt: Biol. (2001) 11:1695–1699.
  • RENGARAJAN J, SZABO SJ, GLIMCHER LH: Transcriptional regulation of Thl/Th2 polarization. Inonunol. Today (2000) 21:479–483.
  • BALAMUTH F, LEITENBERG D, UNTERNAEHRER J et al.: Distinct patterns of membrane microdomain partitioning in Thl and Th2 cells. Inonunio, (2001) 15:729–738.
  • D'AMBROSIO D, IELLEM A, COLANTONIO L et al.: Localization of Th-cell subsets in inflammation: differential thresholds for extravasation of Thl and Th2 cells. Inonunol. Today(2000) 21:183–186.
  • CHTANOVA T, MACKAY CR: T-cell effector subsets: extending the Thl/Th2 paradigm. Adv. Inonunol. (2001) 78:233–266.
  • LOZA MJ, PERUSSIA B: Final steps of natural killer cell maturation: a model for Type 1-type 2 differentiation? Nat. Inonunol (2001) 917–24:917–924.
  • READ S, POWRIE F: CD4(+) regulatory T-cells. Carr: Opin. Cell Biol. (2001) 13:644–649.
  • YOON C, JOHNSTON SC, TANG J et al.: Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12. EMBO J. (2000) 19:3530–3541.
  • ROGGE L, PAPI A, PRESKY DH et al:Antibodies to the IL-12 receptor 13 2 chain mark human Thl but not Th2 cells in vitro and in vivo. J. Inonunol. (1999) 162:3926–3932.
  • WU C, WANG X, GADINA M et al.: IL-12 receptor beta 2 (IL-12R 32)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. J. Inonunol. (2000) 165:6221–6228.
  • SHIMODA K, KATO K, AOKI K et al: Tyk2 plays a restricted role in IFN a signaling, although it is required for IL-12-mediated T-cell function. Inonunio, (2000) 13:561–571.
  • WURSTER AL, TANAKA T, GRUSBY MJ: The biology of Stat4 and Stat6. (2000) 19:2577–2584.
  • LAWLESS VA, ZHANG S, OZES ON et al.: Stat4 regulates multiple components of IFN-y-inducing signaling pathways. Immunol. (2000) 165:6803–6808.
  • YANG J, ZHU H, MURPHY TL et al.: IL-18-stimulated GADD45 (3 required in cytokine-induced but not TCR-induced, IFN-y production. Nat. Immunol. (2001) 2:157–164.
  • STOBIE L, GURUNATHAN S, PRUSSIN et al.: The role of antigen and IL-12 in sustaining Thl memory cells in vivo: IL-12 is required to maintain memory/effector Thl cells sufficient to mediate protection to an infectious parasite challenge. Proc. Nati Acad. Sri. USA (2000) 97:8427–8432.
  • SMITS HH, VAN RIETSCHOTEN JG, HILKENS CM et al.: IL-12-induced reversal of human Th2 cells is accompanied by full restoration of IL-12 responsiveness and loss of GATA-3 expression. Ear: Immunol. (2001) 31:1055–1065.
  • MELERO I, MAZZOLINI G, NARVAIZA et al.: IL-12 gene therapy for cancer: in with other immunotherapies. Trends Immunol (2001) 22:113–115.
  • SMITS HH, HILKENS CM, KALINSKI Pet al.: How to deal with polarized Th2 cells: exploring the Achilles' heel. Int. Arch. Allergy Inamunoi (2001) 126:102–110.
  • BRYAN SA, O'CONNOR BJ, MATTI S et al.: Effects of recombinant human interleukin-1 2 on eosinophils, airway hyper-responsiveness and the late asthmatic response. Lancet (2000) 356:2149–2153.
  • •Clinical trial of IL-12 in asthma.
  • HASKO G, SZABO C: IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T-helper 1/T helper 2 responses. Br. Pharmacol. (1999) 127:1295–1304.
  • BOIRIVANT M, FUSS IJ, FERRONI L et al.: Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis. Immunol. (2001) 166:3522–3532.
  • BRAUN MC, KELSALL BL: Regulation ofinterleukin-1 2 production by G-protein-coupled receptors. Microbes Infect. (2001) 3:99–107.
  • MAKHLOUF K, COMABELLA M, IMITOLA J et al.: Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis. J. (2001) 117:156–165.
  • KARP CL, BIRONC CA, IRAN DN: Interferon in multiple sclerosis: is IL-12 suppression the key? Immunol. Today(2000) 21:24–28.
  • COSTA GL, SANDORA MR, NAKAJIMA A et al.: Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T-cell delivery of the IL-12 p40 subunit.' Immunol. (2001) 167:2379–2387.
  • WALTER MJ, KAJIWARA N, KARANJA P et al.: Interleukin-1 2 p40 production by barrier epithelial cells during airway inflammation. I Exp. Med. (2001) 193:339–351.
  • •Airway epithelial cells produce IL-12 p40 in asthma.
  • ORTMANN R, SMELTZ R, YAP G et al.:A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis. .1. Immunol. (2001) 166:5712–5719.
  • MURPHY TL, GEISSAL ED, FARRAR JD, MURPHY KM: Role of the Stat4 N domain in receptor proximal tyrosine phosphorylation. Mol. Cell. Biol (2000) 20:7121–7131.
  • FRANCHIMONT D, GALON J, GADINA M et al.: Inhibition of Thl immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T-lymphocytes. Immunol. (2000) 164:1768–1774.
  • COON ME, DIEGEL M, LESHINSKY N,KLAUS SJ: Selective pharmacologic inhibition of murine and human IL-12-dependent Thl differentiation and IL-12 signaling. Immunoi (1999) 163:6567–6574.
  • OPPMANN B, LESLEY R, BLOM B et al.:Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13:715–725.
  • •Novel composite cytokine, IL-23, related to IL-12, that plays a role in Thl cell function.
  • WIEKOWSKI MT, LEACH MW, EVANS EW et al.: Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility and premature death. I Immunol. (2001) 166:7563–7570.
  • SZABO SJ, KIM ST, COSTA GL et al.: Anovel transcription factor, T-bet, directs Thl lineage commitment. Cell (2000) 100:655–669.
  • MULLEN AC, HIGH FA, HUTCHINS AS et al.: Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science (2001) 292: 1907-1910.
  • ••T-bet is a master switch of Thl celldifferentiation.
  • LIGHVANI AA, FRUCHT DM, JANKOVIC D et al.: T-bet is rapidly induced by interferon-yin lymphoid and myeloid cells. Proc. Nati Acad. Sci. USA (2001) 98:15137–15142.
  • FINOTTO S, NEURATH MF, GLICKMAN JN et al.: Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science (2002) 295:336–338.
  • ••Suggests that T-bet deficiency may beassociated with asthma.
  • SZABO SJ, SULLIVAN BM, C et al.: Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T-cells. Science (2002) 295:338–342.
  • SIMS JE: IL-1 and IL-18 receptors and their extended family. Curt: Opin. Immunol (2002) 14:117–122.
  • MCINNES IB, GRACIE JA, LEUNG BP et al.: Interleukin-18: a pleiotropic participant in chronic inflammation. Immunol. Today (2000) 21:312–315.
  • SMELTZ RB, CHEN J, HU-LI J, VACH EM: Regulation of interleukin (IL)-18 receptor a chain expression on CD4(+) T-cells during T-helper (Th) 1/Th2 differentiation. Critical downregulatory role. Med. (2001) 194:143–154.
  • NAKAHIRA M, TOMURA M, IWASAKI M et al.: An absolute requirement for STAT4 and a role for IFN-y as an amplifying factor in IL-12 induction of the functional IL-18 receptor complex. Immunol. (2001) 167:1306–1312.
  • CHAN WL, PEJNOVIC N, LEE CA, AL-ALI NA: Human IL-18 receptor and ST2L are stable and selective markers for the respective Type 1 and Type 2 circulating lymphocytes.' Immunol. (2001) 167:1238–1244.
  • •IL-18R and ST2L are respective markers of Thl and Th2 cells in human.
  • CHANG JT, SEGAL BM, NAKANISHI K al.: The costimulatory effect of IL-18 on the induction of antigen-specific IFN-y production by resting T-cells is IL-12 dependent and is mediated by upregulation of the IL-12 receptor in subunit. Ear: (2000) 30:1113–1119.
  • NEIGHBORS M, XU X, BARRAT FJ et al.: A critical role for interleukin-18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon y production. J. Exp. Med. (2001) 194:343–354.
  • HOFSTRA CL, VAN ARK I, HOFMAN G et al.: Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia and serum IgE levels. .1 Irninunol. (1998) 161:5054–5060.
  • WALTER DM, WONG CP, H. DR et al: IL-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyper-reactivity. .1 Irninunol (2001) 166:6392–6398.
  • WILD JS, SIGOUNAS A, SUR N et al: IFN-y-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines and airway eosinophilia in a mouse model of allergic asthma. .1 Irninunol (2000) 164:2701–2710.
  • DINARELLO CA: Targeting interleukin-18 with interleukin-18 binding protein. Ann Rheum Dis. (2000) 59S1:17–20.
  • PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. Clin. Invest. (2001) 108:1825–1832.
  • •Suggests the potential therapeutic utility of IL-18BP in arthritis.
  • FIORUCCI S: NO-releasing NSAIDs are caspase inhibitors. Trends Innnunol. (2001) 22:232–235.
  • CHEN Q, GHILARDI N, WANG H et al.: Development of Thl-type immune responses requires the Type I cytokine receptor TCCR. Nature (2000) 407:916–920.
  • YOSHIDA H, HAMANO S, SENALDI G et al.:WSX-1 is required for the initiation of Thl responses and resistance to L. major infection. InnnuniO, (2001) 15:569–578.
  • VENKATARAMAN C, SCHAEFER G, SCHINDLER U: Chandra, a novel four-transmembrane domain protein differentially expressed in helper Type 1 lymphocytes. .1 Irninunol. (2000) 165:632–636.
  • CASTRO AG, HAUSER TM, COCKS BGet al.: Molecular and functional characterization of mouse signaling activation molecule (SLAM): differential expression and responsiveness in Thl and Th2 cells.' Immunol. (1999) 163:5860–5870.
  • WU C, NGUYEN KB, PIEN GC et al.: controls T cell responses to virus and terminal differentiation of TH2 cells. Nat. Immunol (2001) 2:410–414.
  • •SAP may be a target for irnmunoregulation.
  • LATOUR S, GISH G, HELGASON CD et al.: Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat. Immunol (2001) 2:681–690.
  • DEMEURE CE, WOLFERS J, MARTIN-GARCIA N et al: Tlymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur. Cancer (2001) 37:1709–1718.
  • LIM YC, XIE H, COME CE et al: IL-12, STAT4-dependent upregulation of CD4(+) T cell core 2 3–1,6-n-acetylglucosaminyl-transferase, an enzyme essential for biosynthesis of P-selectin ligands. .1 Immunol (2001) 167:4476–4484.
  • OGAWA K, TANAKA K, ISHII A et aL: A novel serum protein that is selectively produced by cytotoxic lymphocytes. .1 Immunol (2001) 166:6404–6412.
  • MONNEY L, SABATOS CA, GAGLIA JL et al. Thl -specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 415:536–541.
  • •Novel surface molecule that seems important for Thl cell functions. Also see reference 18.
  • BIEDERMANN T, ZIMMERMANN S, HIMMELRICH H et al.: IL-4 instructs TH1 responses and resistance to Leishrnania major in susceptible BALB/c mice. Nat. Immunol (2001) 2:1054–1060.
  • •IL-4 may promote Thl cell development when present exclusively during DC activation.
  • ZHU J, GUO L, WATSON CJ et al: Stat6is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. Immunol (2001) 166:7276–7281.
  • DUMONT FJ, STARUCH MJ, FISCHER P et al.: Inhibition of T cell activation by pharmacologic disruption of the MEK1/ ERK MAPK or calcineurin signaling pathways results in differential modulation of cytokine production. Immunol (1998) 160:2579–2589.
  • RENGARAJAN J, TANG B, GLIMCHER LH: NFATc2 and NFATc3 regulate TH2 differentiation and modulate TCR-responsiveness of naïve TH cells. Nat. Immunol (2002) 3:48–54.
  • LIEBERSON R, MOWEN KA, MCBRIDE KD et al: Tumour necrosis factor receptor-associated factor (TRAF)2 represses the T-helper cell Type 2 response through interaction with NFAT-interacting protein (NIP45). .1 Exp. Med. (2001) 194:89–98.
  • CASOLARO V, KEANE-MYERS AM, SWENDEMAN SL et al.: Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter. Biol. Chem. (2000) 275:36605–36611.
  • KIM J, HO IC, GRUSBY M, GLIMCHER: The transcription factor c-Maf controls the production of IL-4 but not other Th2 cytokines. IrninuniO, (1999) 10:745–751.
  • •Unique role of c-Maf in IL-4 production.
  • PAUZA ME, NGUYEN A, WOLFE T et al.: Variable effects of transgenic c-Maf on autoimmune diabetes. Diabetes (2001) 50:39–46.
  • BLANCHARD AD, PAGE KR, WATKIN H et al: Identification and characterization of SKAT-2, a novel Th2-specific zinc finger gene. Eur. .1 Innnunol (2000) 30:3100–3110.
  • MOHRS M, BLANKESPOOR CM, WANG ZE et al.: Deletion of a co-ordinate regulator of Type 2 cytokine expression in mice. Nat. Immunol. (2001) 2:842–847.
  • NAWIJN MC, DINGJAN GM, R et al.: Enforced expression of GATA-3 in transgenic mice inhibits Thl differentiation and induces the formation of a Tl/ST2-expressing Th2-committed T cell compartment in vivo. .1. Innnunol (2001) 167:724–732.
  • DAS J, CHEN CH, YANG L et al: A critical role for NF-1( B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Innnunol (2001) 2:45–50.
  • KIMURA M, KOSEKI Y, YAMASHITA M et al.: Regulation of Th2 cell differentiation by inel- 1 8, a mammalian polycomb group gene. Immunity(2001) 15:275–287.
  • ZHOU M, OUYANG W, GONG Q et al.: Friend of GATA-1 represses GATA-3-dependent activity in CD4(+) T cells. Exp. Med. (2001) 194:1461–1471.
  • FINOTTO S, DE SANCTIS GT, LEHR HA et al.: Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression.' Exp. Med. (2001) 193:1247–1260.
  • •Suggests the potential utility of local blockade of GATA3 for treatment of allergy.
  • ODA N, MINOGUCHI K, YOKOE T et al.: Effect of suplatast tosilate (IPD-1151T) on cytokine production by allergen-specific human Thl and Th2 cell lines. Life Se/. (1999) 65:763–770.
  • TAMAOKI J, KONDO M, SAKAI N et al.: Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group. Lancet (2000) 356:273–278.
  • ••A chemical compound inhibitor of Th2cytokine production has beneficial effect in asthma.
  • CHIN JE, HATFIELD GA, WINTERROWD GE et al.: Preclinical evaluation of anti-inflammatory activities of the novel pyrrolopyrimidine PNU-142731A, a potential treatment for asthma. Pharmacol Exp. The,: (1999) 1999:188–195.
  • KATO Y, MANABE T, TANAKA Y, MOCHIZUKI H: Effect of an orally-active Thl/Th2 balance modulator, M50367, on IgE production, eosinophilia and airway hyperresponsiveness in mice. J. Immunol (1999) 162:7470–7479.
  • BORISH LC, NELSON HS, CORREN J et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol (2001) 107:963–970.
  • BROMBACHER F: The role of interleukin-13 in infectious diseases and allergy. Bioessays (2000) 22:647-656.. TOMKINSON A, DUEZ C, CIESLEWICZ G et al.: A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. Immunol (2001) 166:5792–5800.
  • •Suggests the potential of dual IL-4/IL-13 blockade for treatment of asthma.
  • STOLZENBERGER S, HAAKE M, DUSCHL A: Specific inhibition of interleukin-4-dependent Stat6 activation by an intracellularly delivered peptide. Eur. Biochem (2001) 268:4809–4814.
  • WANG LH, YANG XY, KIRKEN RA et al.: Targeted disruption of stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T(H)2 cell response. Blood (2000) 95:1249–1257.
  • NISHIKOMORI R, EHRHARDT RO, STROBER W: T-helper Type 2 cell differentiation occurs in the presence of interleukin-12 receptor 132 chain expression and signaling. J. Exp. Med. (2000) 191:847–858.
  • BIEDERMANN T, MAILHAMMER R, MAI A et al.: Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur. Immunol (2001) 31:1582–1591.
  • •IL-4 can reverse a Thl-mediated response in vivo.
  • MORITA Y, YANG J, GUPTA R et al: Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J. Clin. Invest. (2001) 107:1275–1284.
  • ASADULLAH K, VOLK HD, STERRY W: Novel immunotherapies for psoriasis. Trends Immunol (2002) 23:47–53.
  • GARREN H, RUIZ PJ, WATKINS TA et al.: Combination of gene delivery and DNA vaccination to protect from and reverse Thl autoimmune disease via deviation to the Th2 pathway. Immunity (2001) 15:15–22.
  • ••IL-4 gene therapy for the treatment ofThl-mediated pathology.
  • BLUMCHEN K, KALLINICH T, HAMELMANN E: Interleukin-5: a novel target for asthma therapy. Expert Opin. Biol. Ther. (2001) 1:433–453.
  • VAN WAUWE J, AERTS F, COOLS M et al.: Identification of R146225 as a novel, orally-active inhibitor of interleukin-5 biosynthesis. J. Pharmacol Exp. Ther. (2000) 295:655–661.
  • LECKIE MJ, TEN BRINKE A, KHAN J et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness and the late asthmatic response. Lancet (2000) 356:2144–2148.
  • ZHOU Y, MCLANE M, LEVITT RC: Th2 cytokines and asthma - Interleukin-9 as a therapeutic target or asthma. Respir. Res. (2001) 2:80–84.
  • OSHIMA Y, PURI RK: Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13. Biol. Chem. (2001)276:15185–15191.
  • SCHAEFER G, VENKATARAMAN C, SCHINDLER U: FISP (IL-4-induced secreted protein), a novel cytokine-like molecule secreted by Th2 cells. Immunol (2001) 166:5859–5863.
  • WANG M, TAN Z, ZHANG R et al.: interleukin-24 (MDA-7/M0B-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. Biol. Chem. (2001) In press.
  • PANG, FRENCH D, MAO W et al: Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response and multiorgan inflammation in mice. J. Immunol. (2001) 167:6559–6567.
  • •Together with reference 122, describe a novel Th2 cytokine, IL–25.
  • FORT MM, CHEUNG J, YEN D et al.: IL-25 induces IL-4, IL-5 and IL-13 and Th2-associated pathologies in vivo. Immunity (2001) 15:985–995.
  • •Together with reference 121, describe a novel Th2 cytokine, IL–25.
  • MEISEL C, BONHAGEN K, LOHNING et al.: Regulation and function of Ti! 5T2 expression on CD4+ T-cells: induction of Type 2 cytokine production by Tl/5T2 cross-linking. J. Immunol (2001) 166:3143–3150.
  • CARTER RW, SWEET MJ, XU D et al: Regulation of ST2L expression on T-helper (Th) Type 2 cells. Eur. Immunol (2001) 31:2979–2985.
  • LAMBRECHT BN, DE VEERMAN M, COYLE Al et al.: Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. I Clin. Invest. (2000) 106:551–559.
  • WALZL G, MATTHEWS S, KENDALL S et al.: Inhibition of Tl/ST2 during respiratory syncytial virus infection prevents T-helper cell Type 2 (Th2)- but not Thl-driven immunopathology. I Exp. Med. (2001) 193:785–792.
  • TOWNSEND MJ, FALLON PG, MATTHEWS DJ et al: Tl/5T2-deficient mice demonstrate the importance of Ti! 5T2 in developing primary T-helper cell Type 2 responses. J. Exp. Med. (2000) 191:
  • SENN KA, MCCOY KD, MALOY KJ et al.: Ti-deficient and Ti-Fc-transgenic mice develop a normal protective Th2-type immune response following infection with Nippostrongylus brasiliensis. Eur. I Immunol (2000) 30:1929–1938.
  • MCGUIRK P, MCCANN C, MILLS KH: Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin-10 production by dendritic cells: A novel strategy for evasion of protective T-helper Type 1 responses by Bordetella pertussis. J. Exp. Med. (2002) 195:221–231.
  • NAGATA K, TANAKA K, OGAWA K et al.: Selective expression of a novel surface molecule by human Th2 cells in vivo. Immunol. (1999) 162:1278–1286.
  • ANNUNZIATO F, COSMI L, MANETTI R et al.: Reversal of human allergen-specific CRTH2 TH2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide. J. Allergy Clin. Immunoi (2001) 108:815–821.
  • COSMI L, ANNUNZIATO F, GALLI MIG et al.: CRTH2 is the most reliable marker for the detection of circulating human Type 2 Th and Type 2 T cytotoxic cells in health and disease. Ear: Immunol. (2000) 30:2972–2979.
  • NAGATA K, HIRAI H, TANAKA K et al.: CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. (1999) 459:195–199.
  • HIRAI H, TANAKA K, YOSHIE 0 et al.: Prostaglandin D2 selectively induces chemotaxis in T-helper Type 2 cells, eosinophils and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. (2001) 193:255–261.
  • ••The Th2-associated cell surface molecule,CRTH2, is a receptor for PGD2.
  • FUJITANI Y, KANAOKA Y, ARITAKE K et al.: Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. Immunol. (2002) 168:443–449.
  • ROGGE L, BIANCHI E, BIFFI M et al.: Transcript imaging of the development of human T-helper cells using oligonucleotide arrays. Nat. Genet (2000) 25:96–101.
  • •First evidence for defmed differences in gene expression profiles between Thl and Th2 cells.
  • CHTANOVA T, KEMP RA, SUTHERLAND AP et al.: Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) Type 1 and Type 2 T-cells. I Immunol (2001) 167:3057–3063.
  • AKIRA S, TAKEDA K, KAISHO T: Toll- receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. (2001) 2:675–680.
  • SCHNARE M, BARTON GM, HOLT AC et al.: Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. (2001) 2:947–950.
  • ARKWRIGHT PD, DAVID TJ: Intradermal administration of a killed Mycobacterium vaccaesuspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. Allergy Clin. Immunol. (2001) 107:531–534.
  • •Suggests the utility of a bacterial product for treatment of atopy.
  • CAMPORATA L, CORKHILL A, LONG H et al.: Effects of intradermal injection of 5RL172 on allergen-induced airway responses and IL-5 generation by PBMC in asthma. Respic Crit. Care Med. (2000) 161:S477.
  • SHIRTCLIFFE PM, EASTHOPE SE, CHENG S et al.: The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am.! Respic Crit. Care Med (2001) 163:1410–1414.
  • BALAGON MV, TAN PL, PRESTIDGE R et al.: Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated Mycobacterium vaccae (PVAC): results of an open-label trial. Clin. Exp. Dermatol. (2001) 26:233–241.
  • ROOK GA, RISTORI G, SALVETTI M et al.: Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune disorders. Immunol. Today (2000) 21:503–508.
  • KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev Immunol. (2002) 20:709–760.
  • •Excellent review of CpG ODN biology and potential therapeutic applications.
  • BAUER S, KIRSCHNING CJ, HACKER H et al.: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Nati Acad. Sci USA (2001) 98:9237–9242.
  • BALLAS ZK, KRIEG AM, WARREN T et al.: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. (2001) 167:4878–4886.
  • TIGHE H, TAKABAYASHI K, SCHWARTZ D et al.: Conjugation of immunostimulatory DNA to the short allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. (2000) 106:124–134.
  • GOODRIDGE HS, WILSON EH, HARNETT W et al.: Modulation of macrophage cytokine production by ES-62, a secreted product of the filarial nematode Acanthocheilonema vitae. J. Immunol (2001) 167:940–945.
  • ELLIOTT DE, URBAN JFJ, ARGO CK, WEINSTOCK JV: Does the failure to acquire helminthic parasites predispose to Crohn's disease? FASEB (2000) 14: 1848-1855.
  • MILLER RL, GERSTER JF, OWENS ML et al.: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. (1999) 21:1–14.
  • HEMMI H, KAISHO T, TAKEUCHI 0 et al.: Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. (2002) 3:196–200.
  • •Helps elucidate the mode of action of imiquimod-like compounds.
  • WAGNER TL, AHONEN CL, AM et al.: Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. (1999) 191:10–19.
  • O'REGAN AW, NAU GJ, CHUPP GL, BERMAN JS: Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol. Today (2000) 21:475–478.
  • ASHKAR S, WEBER GE V et al.: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science (2000) 287:860–864.
  • CHABAS D, BARANZINI SE, D et al.: The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science (2001) 294:1731–1735.
  • •Suggests a role for osteopontin in the pathology of MS.
  • MURRAY JS: How the MHC selects Thl/ Th2 immunity. Immunol. Today (1998) 19:157–163.
  • ALLEVA DG, CROWE PD, JIN L et al.: A disease-associated cellular immune response in Type 1 diabetics to an immunodominant epitope of insulin. Clin. Invest. (2001) 107:173–180.
  • KAPPOS L, COMI G, PANITCH H et al: Induction of a non-encephalitogenic Type 2 T-helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. Nat. Med. (2000) 6:1176–1182.
  • ••An APL can induce antigen-specific Th2immune deviation in MS.
  • CHEN M, GRAN B, COSTELLO K et aL: Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler (2001) 7:209–219.
  • PAZ I, ELIAS D, AVRON A et al: I3-cell function in new-onset Type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomized, double-blind, Phase II trial. Lancet (2001) 358: 1749-1753.
  • ••The hsp60 peptide analogue, DiaPep277may have therapeutic activity in IDDM.
  • SPORICI RA, PERRIN PJ: Costimulation of memory T-cells by ICOS: a potential therapeutic target for autoimmunity? Clin. Inonunol. (2001) 100:263–269.
  • TESCIUBA AG, SUBUDHI S, ROTHER RP et al.: Inducible costimulator regulates Th2-mediated inflammation but not Th2 differentiation, in a model of allergic airway disease.' Inonunol. (2001) 167:1996–2003.
  • SUN Y, UN X, CHEN HM et al: Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis." Inonunol (2002) 168:1457–1465.
  • CHAPOVAL AI, NI J, LAU JS et aL: B7-H3: a costimulatory molecule for T-cell activation and IFNI/ production. Nat. Inonunol (2001) 2:269–274.
  • SALLUSTO F, MACKAY CR, LANZAVECCHIA A: The role of chemokine receptors in primary, effector and memory immune responses. Ann. Rev Inonunol (2000) 18:593–620.
  • LUTHER SA,CYSTERJG: Chemokines as regulators of T-cell differentiation. Nat. Inonunol (2001) 2:102–107.
  • KARPUS WJ,J. KK: MIP-lalpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Thl/Th2 lymphocyte differentiation. I Leukoc. Biol. (1998) 62:681–687.
  • ALIBERTI J, REIS E SOUSA C, SCHITO et al.: CCR5 provides a signal for microbial induced production of IL-12 by CD8a+ dendritic cells. Nat. Inonunol. (2000) 1:83–87.
  • GU L, TSENG S, HORNER P.M et al: Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature (2000) 404:407–411.
  • KIM Y, KUZIEL WA et al.: Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2)..1. Iminunol. (2001) 166:5183–5192.
  • PARK MK, HOFFMANN KF, CHEEVER AW et al.: Patterns of chemokine expression in models of Schistosoma inansoni inflammation and infection reveal relationships between Type 1 and Type 2 responses and chemokines in vivo. Infect. Inman. (2001) 69:6755–6768.
  • KIM CH, ROTT L, KUNKEL EJ et al: Rules of chemokine receptor association with T cell polarization in vivo. j Clin. Invest. (2001) 108:1331–1339.
  • •Complex patterns of chemokine receptor expression on various T-cell subsets.
  • GERARD C, ROLLINS BJ: Chemokines and disease. Nat. Inonunol. (2001) 2:108–115.
  • ROSSI D, ZLOTNIK A: The biology of chemokines and their receptors. Ann. Rev Inintunol (2000) 18:217–242.
  • FRATICELLI P, SIRONI M, BIANCHI G et al.: Fractalkine (CX3CL1) as an amplification circuit of polarized Thl responses.j Clin. Invest. (2001) 107:1173–1181.
  • PANINA-BORDIGNON P, PAPI A, MARIANI M et al: The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. Clin. Invest. (2001) 107:1357–1364.
  • IELLEM A, MARIANI M, LANG R et al: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4HCD25(+) regulatory T-cells. Exp. Med. (2001) 194:847–854.
  • ELEWAUT D, KRONENBERG M: Molecular biology of NK T cell specificity and development. Sentin. Iminunol. (2000) 12:561–568.
  • KAWANO T, CUI J, KOEZUKA Y et al: CDid-restricted and TCR-mediated activation of valphal4 NKT cells by glycosylceramides. Science (1997) 278: 1626-1629.
  • NAKAGAWA R, NAGAFUNE I, TAZUNOKI Y et al.: Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by a-galactosylceramide in mice. .1 I,nmunol. (2001) 166:6578–6584.
  • SINGH N, HONG S, SCHERER DC et al.: Activation of NK T-cells by CD1d and a-galactosylceramide directs conventional T-cells to the acquisition of a Th2 phenotype. j. Inonunol (1999) 163:233–2377.
  • HONG S, WILSON MT, SERIZAWA I et al.: The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. (2001) 7:1052–1056.
  • •Together with references 184–187 demonstrate that activation of NKT cells with a-GalCer has beneficial effects in Thl-mediated autoimmunity that are associated with Th2 deviation.
  • SHARIF S, ARREAZA GA, ZUCKER P et al.: Activation of natural killer T cells by a-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. (2001) 7:1057–1062.
  • JAHNG AW, MARICIC I, PEDERSEN B et al.: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. Exp. Med. (2001) 194:1789–1799.
  • SINGH AK, WILSON MT, HONG S et al.: Natural killer T-cell activation protects mice against experimental autoimmune encephalomyelitis. Exp. Med. (2001) 194:1801–1811.
  • MIYAMOTO K, MIYAKE S, YAMAMURA T: A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature (2001) 413:531–534.
  • ••An analogue of a-GalCer preferentiallyinduces IL-4 production by NKT cells and prevents EAE.
  • THORBECKE GJ, UMETSU DT, DEKRUYFF RH et al: When engineered to produce latent TGF-I31, antigen specific T cells downregulate Thl cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev (2000) 11:89–96.
  • WEINER HL: Oral tolerance: immune mechanisms and the generation of Th3-type TGF-P-secreting regulatory cells. Microbes Infect. (2001) 3:947–954.
  • KUKREJA A, COST G, MARKER J et al: Multiple immuno-regulatory defects in type-1 diabetes.' Clin. Invest. (2002) 109:131–140.
  • ZHANG X, IZIKSON L, LIU L, WEINER HL: Activation of CD25+CD4+ regulatory T cells by oral antigen administration. Immunol (2001) 167:4245–4253.
  • TAYLOR A, NAMBA K: In vitro induction of CD25 CD4 regulatory T cells by the neuropeptide a-melanocyte stimulating hormone (a-MSH). Immunol Cell Biol. (2001) 79:358–367.
  • YAMAGIWA S, GRAY JD, HASHIMOTO S, HORWITZ DA: A role for TGF-B in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. " Immunol (2001) 166:7282–7289.
  • •Describes method to generate Treg cells from human blood.
  • JONULEIT H, SCHMITT E, STEINBRINK K, ENK AH: Dendritic cells as a tool to induce anergic and regulatory T-cells. Trends Immunol (2001) 22:394–400.
  • DHODAPKAR MV, STEINMAN RM, KRASOVSKY J et al.: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. (2001) 193:233–238.
  • READ, VAN KOOTEN C, VAN MEIJGAARDEN KE et al.: Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood (2000) 95:3162–3167.
  • ••Dexarnethasone confers tolerogenicpotential to DCs.
  • KERO J, GISSLER M, HEMMINKI E, ISOLAURI E: Could TH1 and TH2 diseases coexist? Evaluation of asthma incidence in children with coeliac disease, Type 1 diabetes, or rheumatoid arthritis: A register study. I Allergy Clin. Immunol (2001) 108:781-783.. SALVI SS, SURESH BABU K, HOLGATE ST: Is asthma really due to a polarized T-cell response toward a helper T cell Type 2 phenotype? Am. I Respir Crit. Care Med. (2001) 164:1343–1346.
  • •Questions the role of Th2 cells in asthma.
  • HANSEN G, BERRY G, DEKRUYFF RH, UMETSU DT: Allergen-specific Thl cells fail to counterbalance Th2 cell-induced airway hyper-reactivity but cause severe inflammation.' Clin. Invest. (1999) 103:175-183.. PEDOTTI R, MITCHELL D, WEDEMEYER J et al.: An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol (2001) 2:216–222.
  • NIH clinical trials: http://www.clinicaltrials.gov
  • Vertex Pharmaceuticals, Inc.: http://www.vpharm.com
  • Protein Design Labs. Press release: Protein Design Labs announces promising preliminary clinical results with SMARTTm antigamma interferon; plans additional development. November 5, 2001: http://www.pdl.com
  • Boston Life Sciences, Inc. Press release: Boston Life Sciences signs licensing agreement with Pfizer for allergy and asthma. September 13, 1999: http://www.bostonlifesciences.com
  • Avanir Pharmaceuticals. Press release: Avanir Pharmaceuticals identifies small molecule found to be effective in regulating the causes of allergy and asthma. November 19, 2001: http://www.avanir.com
  • Protein Design Labs. Press release: Protein Design Labs begins Phase II study of humanised antiIL-4 antibody in asthma. October 9, 2001: http://www.pdl.com
  • Immunex Corporation. Press release: Data from two of three studies with NUVANCETm (soluble IL-4 receptor) analysed. No apparent relief for uncontrolled asthma patients, awaiting data from ongoing study as steroid replacement. March 22, 200:://www.immunex.com
  • Bayer AG: http://www.bayer.com
  • SR Pharma: http://www.srpharma.com

Websites

  • Coley Pharmaceutical Group: http://www.coleypharma.com
  • Peptor. Press release: US clinical trial begins for Diapep277TM, new drug shown to arrest progression of Type 1 diabetes. January 14, 2002: http://www.peptor.com

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.